JP2024518665A - 加齢に伴う疾患を防止および／または処置することにおける使用のためのｓｉｒｔ６のバリアント - Google Patents

加齢に伴う疾患を防止および／または処置することにおける使用のためのｓｉｒｔ６のバリアント Download PDF

Info

Publication number
JP2024518665A
JP2024518665A JP2024515284A JP2024515284A JP2024518665A JP 2024518665 A JP2024518665 A JP 2024518665A JP 2024515284 A JP2024515284 A JP 2024515284A JP 2024515284 A JP2024515284 A JP 2024515284A JP 2024518665 A JP2024518665 A JP 2024518665A
Authority
JP
Japan
Prior art keywords
sirt6
nucleic acid
vector
seq
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518665A5 (https=
Inventor
ゴルブノワ，ヴェラ
セルアノフ，アンドレイ
ソ，ヨウシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
University of Rochester
Original Assignee
Columbia University in the City of New York
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York, University of Rochester filed Critical Columbia University in the City of New York
Publication of JP2024518665A publication Critical patent/JP2024518665A/ja
Publication of JP2024518665A5 publication Critical patent/JP2024518665A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K7/00—Arrangements for handling mechanical energy structurally associated with dynamo-electric machines, e.g. structural association with mechanical driving motors or auxiliary dynamo-electric machines
    • H02K7/18—Structural association of electric generators with mechanical driving motors, e.g. with turbines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Power Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024515284A 2021-05-14 2022-05-13 加齢に伴う疾患を防止および／または処置することにおける使用のためのｓｉｒｔ６のバリアント Pending JP2024518665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188573P 2021-05-14 2021-05-14
US63/188,573 2021-05-14
PCT/US2022/029213 WO2022241228A2 (en) 2021-05-14 2022-05-13 Variants of sirt6 for use in preventing and/or treating age-related diseases

Publications (2)

Publication Number Publication Date
JP2024518665A true JP2024518665A (ja) 2024-05-01
JP2024518665A5 JP2024518665A5 (https=) 2025-05-20

Family

ID=84029856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515284A Pending JP2024518665A (ja) 2021-05-14 2022-05-13 加齢に伴う疾患を防止および／または処置することにおける使用のためのｓｉｒｔ６のバリアント

Country Status (5)

Country Link
US (1) US20240277868A1 (https=)
EP (1) EP4338267A4 (https=)
JP (1) JP2024518665A (https=)
CA (1) CA3218849A1 (https=)
WO (1) WO2022241228A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630038A1 (en) * 2022-12-08 2025-10-15 Genflow Biosciences Srl Variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease
EP4665406A1 (en) * 2023-02-14 2025-12-24 The Trustees of Columbia University in the City of New York Crispr-transposon systems and components
WO2026062177A1 (en) 2024-09-20 2026-03-26 Genflow Biosciences Srl Variants of sirtuin 6 for the treatment of muscular diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110113498A1 (en) * 2008-05-15 2011-05-12 Westphal Christoph H Sirt1 polymorphic variants and methods of use thereof
JP2015193582A (ja) * 2014-03-28 2015-11-05 国立大学法人 東京大学 イミダゾールジペプチドを含む剤
WO2017201425A1 (en) * 2016-05-20 2017-11-23 The Trustees Columbia University In The City Of New York Anabolic enhancers for ameliorating neurodegeneration
AU2017378427A1 (en) * 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery

Also Published As

Publication number Publication date
US20240277868A1 (en) 2024-08-22
CA3218849A1 (en) 2022-11-17
WO2022241228A3 (en) 2023-01-05
EP4338267A2 (en) 2024-03-20
WO2022241228A2 (en) 2022-11-17
EP4338267A4 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
Marchi et al. Akt‐mediated phosphorylation of MICU1 regulates mitochondrial Ca2+ levels and tumor growth
Uehara et al. Start codon disruption with CRISPR/Cas9 prevents murine Fuchs’ endothelial corneal dystrophy
JP2024518665A (ja) 加齢に伴う疾患を防止および／または処置することにおける使用のためのｓｉｒｔ６のバリアント
Sun et al. Sam68 is required for DNA damage responses via regulating poly (ADP-ribosyl) ation
Wang et al. Human CST suppresses origin licensing and promotes AND-1/Ctf4 chromatin association
CA2977685A1 (en) Homologous recombination factors
JP2025108697A (ja) Ａｌｔがんの処置
US20240366736A1 (en) Method for managing pain
CA3236182A1 (en) Compositions and systems for rna-programable cell editing and methods of making and using same
CN107532169A (zh) 用于治疗杜兴氏肌肉营养不良症的发动蛋白2抑制剂
Cheng et al. Loss of fragile WWOX gene leads to senescence escape and genome instability
Li et al. Inactivation of Invs/Nphp2 in renal epithelial cells drives infantile nephronophthisis like phenotypes in mouse
Wang et al. Restoration of SIRT3 Expression in Aged Mice Alleviates UUO‐Induced Renal Fibrosis by Reducing GSK‐3β Hyperacetylation
WO2013020366A1 (zh) 乙酰胆碱酯酶作为核酸酶的应用
Sharma et al. Human telomerase expression is under direct transcriptional control of the telomere-binding-factor TRF2
JP2025541838A (ja) 非アルコール性脂肪性肝疾患の治療のためのサーチュイン６のバリアント
JP2015515485A (ja) Ｒｎａリガーゼ複合体メンバーとしてのアーキアーゼ
EP4121171A1 (en) Pharmaceutical combination for the treatment of myeloproliferative neoplasms
WO2016138340A1 (en) Tumor suppressor sall1 as a therapeutic agent for treating cancer
Shi et al. ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer
CN112107684B (zh) 治疗arid2或hspa1a介导的疾病的方法和组合物
Shen et al. Oncogenic EGFR rewires STING-TBK1 immune machinery by tyrosine phosphorylation to license DNA damage tolerance
WO2024211430A2 (en) Methods and compositions for treating neurodegenerative conditions
Good Unraveling the β Cell Translatome: Elucidation of an ERK/hnRNPK/JUND Axis
JP2025007962A (ja) 変異型ｔｄｐ－４３タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260410